Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070393 | 1.00 | KDM4E (0.74) | KDM4EKMT2ASMN1; SMN2RAB9APDGFRB | |
| SCHEMBL6070391 | 1.00 | KDM4E (0.74) | KDM4EKMT2ASMN1; SMN2RAB9APDGFRB | |
| SCHEMBL29733054 | 1.00 | KDM4E (0.74) | KDM4EKMT2ASMN1; SMN2RAB9APDGFRB | |
| SCHEMBL6070374 | 0.85 | KDM4E (1.00) | KDM4EKMT2ASMN1; SMN2RAB9APDGFRB | |
| SCHEMBL6070375 | 0.85 | KDM4E (1.00) | KDM4EKMT2ASMN1; SMN2RAB9APDGFRB | |
| SCHEMBL21001881 | 0.85 | KDM4E (0.79) | KDM4EKMT2ASMN1; SMN2RAB9APDGFRB | |
| SCHEMBL21040481 | 0.85 | KDM4E (0.70) | KDM4EKMT2ASMN1; SMN2RAB9APDGFRB | |
| SCHEMBL26750753 | 0.85 | KDM4E (0.53) | KDM4EKMT2ASMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL26750756 | 0.84 | KMT2A (0.52) | KDM4EKMT2ASMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL30628958 | 0.84 | KMT2A (0.52) | KDM4EKMT2ASMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | KDM4E 2185/4885KMT2A 3748/4885SMN1; SMN2 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.